Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
We recognize physicians and the demands of continuous learning – especially when treating patients who have rare conditions. …
CSL is a member of PALADIN, a one-of-a-kind consortium that’s bringing together industry leaders and patient advocacy groups.…
Eleven CSL employees spent 24 hours immersed in the daily reality of being an asthma patient. The experience was an introduct…
We asked the leaders of patient advocacy groups – and CSL staff – to explain why rare conditions deserve attention and recogn…
CSL recently joined the nonprofit organization to strengthen patient engagement in Europe. EUPATI educates and supports patie…
Thanks to patient advisory boards, CSL is continuously learning how to partner with patients and make clinical trials less bu…
Patients who have been clinical trial participants have until February 23 to apply for scholarships to attend the conference …
Patients who manage chronic illnesses navigate the line between wanting to be self-sufficient and knowing when to reach out f…
Patient organizations have until February 18 to apply for CSL Behring’s Local Empowerment for Advocacy Development (LEAD) Gra…
Answering CSL.com’s survey, the leaders of nonprofit patient organizations said they are looking forward to a productive year…
As 2023 comes to a close, leaders in patient advocacy shared accomplishments and highlights in CSL.com’s annual survey.
To better understand how patients experience hereditary angioedema (HAE), CSL invited Anthony Castaldo and Henrik Boysen to m…
Americas
Asia Pacific
Middle East
Europe